Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (pah) in spain using reflective multi-criteria decision analysis (mcda)

HIGHLIGHTS

• who: Alberto Jiménez from the Omakase Consulting SL, Madrid, Spain have published the research work: Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA), in the Journal: (JOURNAL)
• what: The aim of this study was to assess the value contribution of the new oral prostacyclin receptor agonist selexipag for PAH treatment in Spain through reflective Multicriteria Decision Analysis (MCDA) methodology. At the time of the study start, the reimbursed price for selexipag had not yet been established in Spain, so . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.